HOME >> MEDICINE >> NEWS
Asthmatx completes enrollment in pivotal study of bronchial thermoplasty

San Francisco, CA, May 21, 2007 Asthmatx, Inc., a medical device company that has developed a catheter-based procedure for the treatment of asthma, announced today the successful completion of enrollment in its pivotal FDA approved IDE study, the Asthma Intervention Research 2 (AIR2) Trial of the Alair Bronchial Thermoplasty System. Bronchial Thermoplasty is a non-drug treatment for asthma under clinical investigation in the United States. The minimally invasive, bronchoscopic procedure uses thermal energy to reduce the airway smooth muscle responsible for constriction in asthma patients.

Leading asthma and bronchoscopy experts are participating in this international, multicenter AIR2 Trial to establish the safety and efficacy of the Alair System. Nearly 300 patients were enrolled in the study during the last 18 months at over 30 world-renowned medical centers including 15 US research hospitals. The AIR2 Trial is the fourth clinical study of the Alair Bronchial Thermoplasty System. To date, over 700 bronchoscopic procedures have been performed on asthma patients.

"We are very pleased to be a participant in this very important AIR2 Trial, the success of which will result in an important advancement in the treatment of severe asthma," states Mario Castro, MD, Associate Professor at the Washington University School of Medicine and Asthma Center, and a Principal Investigator in the AIR2 Trial. "As the lead enrolling center in the United States, we have experienced significant patient interest in bronchial thermoplasty, which we hope may become a new option for patients with difficult-to-treat asthma."

Final results of the first randomized and controlled clinical study of bronchial thermoplasty, the Asthma Intervention Research (AIR) Trial, were also reported today at the annual scientific assembly of the American Thoracic Society (ATS) by Gerard Cox, MB, Professor of Medicine, McMaster University, Canada, and principal investigato
'"/>

Contact: Meghan Oreste
moreste@comcast.net
617-823-1441
Asthmatx
21-May-2007


Page: 1 2

Related medicine news :

1. Acrux completes enrollment in key phase 2 trial
2. MacroChem completes patient enrollment for Phase II trial of EcoNail for treatment of onychomycosis
3. GroPep completes final milestone of the path malaria vaccine initiative
4. Im a Kid Too project completes first phase
5. Approval to start US BTT pivotal trial
6. Bayer and Onyx announce pivotal Nexavar kidney cancer study published in NEJM
7. New data show CAS in clinical practice has comparable MAE rate with pivotal sapphire trial
8. Now is a pivotal point in history to abolish state execution
9. Orqis Medical receives unconditional FDA approval for pivotal trial of percutaneous CHF therapy
10. Childhood obesity indicates greater risk of school absenteeism, Penn study reveals
11. Penn study finds pro-death proteins required to regulate healthy immune function

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/27/2016)... Brooklyn, NY (PRWEB) , ... June 27, 2016 ... ... is using cutting edge technology to revolutionize the emergency ambulance transport experience for ... Many are aware of how Uber has disrupted the taxi industry through the ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/25/2016)... ... ... temporary closing of Bruton Memorial Library on June 21 due to a possible lice infestation, ... aspect of head lice: the parasite’s ability to live away from a human host, and ... necessary one in the event that lice have simply gotten out of control. , As ...
(Date:6/25/2016)... ... , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department ... in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at ... Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 ...
(Date:6/24/2016)... ... 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out of ... verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... throw rocks at my other children and say he was going to kill them. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  Consumers have taken ... regulators/payers have placed more emphasis on patient outcomes. ... support programs in the pharmaceutical industry have evolved ... Consequently, pharmaceutical companies are focusing on becoming more ... providing products and services that improve health. ...
(Date:6/24/2016)... , June 24, 2016   Bay ... Rehabilitation Network,s Dean Center for Tick Borne ... Medicine and Rehabilitation, MIT Hacking Medicine, University of ... Innovation, today announced the five finalists of ... Lyme disease.  More than 100 scientists, clinicians, researchers, ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
Breaking Medicine Technology:
Cached News: